Anti-CGRP migraine therapies vs conventional migraine preventives for tinnitus in people with migraine (COMPACT-PM)
Trial details
- Registry identifier: NCT07655440 on ClinicalTrials.gov
- Phase: Phase 4
- Status: Not yet recruiting (verified at ClinicalTrials.gov 2026-09-26)
- Sponsor: Stanford University
- Planned enrollment: 120
- Estimated completion: Jul 2031 (est.)
- Country: USA
Why this trial matters
Randomized, open-label comparison in people who have both tinnitus and migraine: anti-CGRP agents (galcanezumab, erenumab, eptinezumab, atogepant) against conventional migraine preventives, open-label, in people with both tinnitus and migraine; primary outcome TFI at 24 weeks.
Trial statuses are verified against the ClinicalTrials.gov registry by our weekly automated check. A tracked trial is research in progress — inclusion is not a treatment recommendation, and only the study team can determine eligibility.